Johnson & Johnson stands alone as a leader across the major healthcare industries. It maintains a diverse revenue base, a developing research pipeline, and exceptional cash flow generation that ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced a strategic restructuring plan ...

SHELTON, CONNECTICUT / ACCESS Newswire / July 16, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) ...

The US President announced a list of updates concerning US trade tariffs on Tuesday, including a deal with Indonesia and his ...

J&J (NYSE:JNJ) stock surges rallying peers despite Trump's latest tariff threats on pharma as the company posts a quarterly ...

Seven biotech unicorns are advancing AI-powered drug discovery and development—but must contend with a difficult investing ...

Trackonomy reports cargo theft is a rising issue in supply chains, costing billions while advanced technology helps combat ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

This randomized, double-masked, placebo-controlled, Phase 2 Proof-of-Concept trial of urcosimod to treat NCP was conducted at a single trial site at Tufts Medical Center in Boston, MA, with Pedram ...

Big Pharma hates the telehealth startup. Meme-stock day traders love it. Why CEO Andrew Dudum won’t stop selling GLP-1s, no ...

The first phase of Fujifilm Biotechnologies’ $3.2-billion large-scale cell culture biopharmaceutical manufacturing plant in North Carolina is scheduled to begin operating this year.

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.